VYGR Voyager Therapeutics, Inc.
$1.75▲ +0.57%
Healthcare
Other
Volume 1.66M
Avg Volume (10D) 1.09M
Key Metrics & Fundamentals
Market Cap
$107.83M
P/E Ratio
–
Div Yield
0.00%
52W Range
1.71 - 5.48
% vs 50 MA
-38.28%
% vs 200 MA
-50.05%
RSI-14
26.7
MACD Histogram
-0.0200
Beta (1Y vs SPY)
1.37
Free Cash Flow
-$25.84M
Gross Rev
$3.17M
Gross Profit
$3.17M
EBITDA
-$25.48M
COGS
–
Operating Exp
$29.56M
Operating Income
-$26.39M
EBIT
-$26.39M
Pretax Income
-$24.45M
Net Income
-$24.47M
EPS (Diluted)
-0.40
Price & Volume History
Loading chart…
Recent News
Voyager’s Tau-Targeted Gene Therapy VY1706 and Anti-Tau Antibody VY7523 for Alzheimer’s Disease to Be Featured in Poster Presentations at CTAD 2026
GlobeNewswire · Oct 27, 2026 8:01 AM ET
Voyager Announces CEO Succession Plan, Appoints Robin Swartz President
GlobeNewswire · Oct 21, 2026 8:01 AM ET
Voyager to Present at Upcoming Investor Conferences
GlobeNewswire · Sep 1, 2026 8:00 AM ET
Voyager Therapeutics (VYGR) Reports Q2 Loss, Misses Revenue Estimates
Zacks · Aug 6, 2026 7:10 PM ET
Voyager Therapeutics: Q2 Earnings Snapshot
Associated Press · Aug 6, 2026 4:44 PM ET
Voyager Reports Second Quarter 2026 Financial and Operating Results
GlobeNewswire · Aug 6, 2026 4:01 PM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See VYGR's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.